MetaCap

Rani Therapeutics (RANI) vs Xilio Therapeutics (XLO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xilio Therapeutics (XLO) has outperformed Rani Therapeutics (RANI) over the past year, losing 28.3% versus a loss of 68.6%. Over five years, XLO leads with a -97.3% price change compared with -98.3% for RANI. Rani Therapeutics is the larger company by market cap ($59.0 million vs $53.4 million), about 1.1 times the size, while Xilio Therapeutics is growing revenue faster (+589.9% vs +58.9%).

Xilio Therapeutics converts more of its revenue into profit, with a net margin of -80.1% versus -1817.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RANI-68.64%XLO-28.29%
+5%-33%-72%
Nov 21, 20251 yearNov 20, 2026
RANI-98.50%XLO-97.63%
+5%-49%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RANI versus XLO key metrics
MetricRANIXLO
Share price$0.5111$7.56
Market cap$59.03M$53.40M
1-day change-11.97%-1.11%
YTD return-62.14%-15.63%
1-year return-68.64%-28.29%
5-year return-98.34%-97.29%
P/E ratio (TTM)—11.63
EPS (TTM)$-0.06$0.65
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.63M$43.77M
Revenue growth (YoY)+58.85%+589.88%
Net income (latest FY)$-29.67M$-35.04M
Operating margin-2345.99%-95.92%
Net margin-1817.09%-80.05%
52-week high$1.69$10.71
52-week low$0.502$6.47
Distance from 52-week high-69.76%-29.41%
Analyst consensusstrong_buynone
Avg. price target upside+1308.73%+164.55%
Average volume545.67K11.54K
Shares outstanding115.49M7.06M
Employees6976
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XLO has outperformed RANI by 40.4 percentage points over the past year.
  • Xilio Therapeutics is more profitable, keeping -80.1 cents of every revenue dollar as net income versus -1817.1 cents for Rani Therapeutics.
  • Xilio Therapeutics grew revenue faster in its latest fiscal year (+589.88% vs +58.85%).

About Rani Therapeutics

RANI stock →

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Xilio Therapeutics

XLO stock →

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

RANI vs XLO FAQ

Which is bigger, Rani Therapeutics or Xilio Therapeutics?

Rani Therapeutics (RANI) is larger, with a market capitalization of $59.03M compared with $53.40M for Xilio Therapeutics (XLO).

Which stock has performed better over the past year, RANI or XLO?

XLO returned -28.29% over the past 12 months, compared with -68.64% for RANI (price return, excluding dividends). Past performance does not predict future results.

Are Rani Therapeutics and Xilio Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons